Dr. Martens (LON:DOCS) Price Target Lowered to GBX 360 at Barclays

Dr. Martens (LON:DOCSGet Rating) had its price objective lowered by Barclays from GBX 480 ($6.25) to GBX 360 ($4.69) in a research report released on Wednesday morning, MarketBeat.com reports. The brokerage currently has an overweight rating on the stock.

Separately, Royal Bank of Canada reaffirmed an outperform rating and issued a GBX 375 ($4.89) price objective on shares of Dr. Martens in a report on Monday.

Dr. Martens stock opened at GBX 230.62 ($3.01) on Wednesday. The stock has a 50-day moving average price of GBX 253.58 and a 200 day moving average price of GBX 333.98. The company has a market capitalization of £2.31 billion and a price-to-earnings ratio of 42.41. Dr. Martens has a 52 week low of GBX 206.60 ($2.69) and a 52 week high of GBX 517 ($6.74). The company has a quick ratio of 1.34, a current ratio of 2.24 and a debt-to-equity ratio of 188.65.

In related news, insider Robyn Perriss purchased 15,000 shares of the firm’s stock in a transaction on Monday, January 31st. The stock was bought at an average cost of GBX 303 ($3.95) per share, with a total value of £45,450 ($59,225.96).

About Dr. Martens (Get Rating)

Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. Its product segments include originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name.

Featured Articles

Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.